Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

FATE $5.27 1.5700 +42.43%
ADXS $5.61 0.7500 +15.43%
ZIOP $4.80 0.5300 +12.41%
CVM $0.65 0.0657 +11.24%
ISIS $65.09 5.5400 +9.30%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMGN $6.11 -4.7400 -43.69%
CBMG $12.55 -1.1400 -8.33%
GTXI $0.89 -0.0800 -8.25%
PARD $0.16 -0.0100 -5.88%
GLYC $8.64 -0.4200 -4.64%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

Capecitabine Monotherapy Does Not Improve Survival in Elderly Patients With Early-Stage Breast Cancer

(AACR) Dec 11, 2014 - In elderly breast cancer patients with moderate- to high-risk early-stage disease for whom standard chemotherapy is too toxic, the chemotherapy capecitabine, which causes fewer side effects than the standard chemotherapy agents, did not improve outcomes when tested as monotherapy, according to data from the phase III ICE trial presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 9–13.
read press release 

Adding Ovarian Suppression to Tamoxifen Reduced Recurrence For Some Women With Premenopausal Breast Cancer

(AACR) Dec 11, 2014 - Among premenopausal women with early-stage, hormone receptor-positive breast cancer, adding ovarian suppression to tamoxifen reduced breast cancer recurrence for those who had previously received chemotherapy and remained premenopausal, according to data from the randomized, phase III suppression of ovarian function trial (SOFT) presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 9–13.
read press release 

IBIS-I Trial Finds Tamoxifen Lowered Breast Cancer Rates Among High-Risk Women

(AACR) Dec 11, 2014 - After a median of 16 years of following women at high risk for breast cancer, the International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 9–13.
read press release 

New Treatment Shows Promise in Younger Breast Cancer Patients: Study

(Philadelphia Inquirer/HealthDay News) Dec 11, 2014 - A treatment known as ovarian suppression used along with an anti-estrogen drug normally given to older women appears to greatly reduce the risk of breast cancer recurrence in some younger women, new research suggests.
read article 

Breast Cancer Prevention Drug Gives Lasting Protection, Study Finds

(Los Angeles Times/Science Now) Dec 11, 2014 - Taking the cancer drug tamoxifen for five years drives down the incidence of breast cancer in women at high risk for the disease by close to 30%, researchers have found.
read article (free registration required) 

What's Intriguing and Concerning About Early Results For Keytruda in Breast Cancer

(Forbes) Dec 11, 2014 - At first glance, it’s hard to get excited about the preliminary results of an early phase trial study of pembrolizumab (Keytruda, MK-3475) in women with triple-negative breast cancer (TNBC).
read article 

Phase III Results From German Breast Group (GBG) Demonstrates Superior Activity in High Risk Early Breast Cancer For Nab-Paclitaxel (ABRAXANE®) VS. Solvent-Based Paclitaxel

(Yahoo! Finance) Dec 11, 2014 - Phase III results demonstrate significant pCR (pathological complete response) for nab-paclitaxel in neoadjuvant breast cancer.
read article 

Novel Approach for Estrogen-receptor-positive Breast Cancer Reported

(Loyola Health Sciences) Dec 10, 2014 - Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.
read press release 

Gilead Sued Over 'Exorbitant' Hepatitis C Drug Prices

(Reuters) Dec 10, 2014 - Philadelphia's transportation authority has filed a class action lawsuit accusing Gilead Sciences Inc of charging "exorbitant" prices for its blockbuster hepatitis C drug Sovaldi.
read article 

Chemo Telepharmacy Project Takes Top Award at ASHP

(Medscape Medical News) Dec 10, 2014 - A telepharmacy pilot project allowing licensed pharmacists to supervise the mixing of chemotherapy by pharmacy technicians in areas up to 90 minutes from a prominent cancer center has received national recognition.
read article (free registration required) 

Higher-Earning Physicians Order More Services

(Medscape Medical News) Dec 10, 2014 - CMS data show wide variation in physician payments based on services provided, not the number of patients treated.
read article (free registration required) 

Zydus Cadila Launches Biosimilar of AbbVie's Humira in India

(The Economic Times [New Delhi, India]) Dec 9, 2014 - Drug firm Zydus Cadila today launched biosimilar of Adalimumab, used for treatment of auto immune disorders, at a price much lower than the innovator drug in India.
read article 

Biotechs and Generic Drug Makers Compromise on Biosimilar Lobbying

(Wall Street Journal/Pharmalot blog) Dec 10, 2014 - Biotech and generic drug makers reached a compromise on lobbying state legislature for biosimilar substitution.
read article (paid subscription required) 

Katmai Oncology Group Joins Seattle Cancer Care Alliance Affiliate Network

(Seattle Cancer Care Alliance) Dec 9, 2014 - Katmai Oncology Group has joined the Seattle Cancer Care Alliance (SCCA) Network to become its eleventh affiliate in the greater Northwest. The affiliation will expand local access to cancer treatment options and help foster advances in cancer care.
read press release 

Mistaken Identities Plague Lab Work With Human Cells

(NPR/Shots blog) Dec 9, 2014 - A line of immortal cells, supposedly from a breast cancer patient, turned out to be from a type of skin cancer. The mix-up wasn't discovered until experiments around the world had been contaminated.
read article 

Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors

(Bristol-Myers Squibb) Dec 10, 2014 - Ono Pharmaceutical Co.,Ltd., Bristol-Myers Squibb Company and Kyowa Hakko Kirin Co., Ltd. announced today the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody.
read corporate press release 

Immunovaccine Receives FDA Fast Track Designation for DPX-Survivac for Treatment of Ovarian Cancer

(Immunovaccine) Dec 10, 2014 - Immunovaccine Inc. today announced that DPX-Survivac, the Company's lead cancer vaccine candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) as maintenance therapy in subjects with advanced ovarian, fallopian tube, and peritoneal cancer who have no measureable disease following surgery and front-line platinum/taxane chemotherapy to improve their progression-free survival.
read corporate press release 

FDA Approves Gardasil 9 for Prevention of Certain Cancers Caused by Five Additional Types of HPV

( Dec 10, 2014 - The U.S. Food and Drug Administration today approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human Papillomavirus (HPV). Covering nine HPV types, five more HPV types than Gardasil (previously approved by the FDA), Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.
read press release 

AACR Mourns Loss of Past-President Lee Wattenberg, “Father of Chemoprevention”

(AACR) Dec 10, 2014 - The cancer research community mourns the loss of Lee W. Wattenberg, MD, emeritus professor of laboratory medicine and pathology at the University of Minnesota Masonic Cancer Center in Minneapolis, who died Dec. 9, 2014, at the age of 92.
read press release 

Susan G. Komen Brinker Awardees for Scientific Distinction Deliver Lectures; Honored Today at San Antonio Breast Cancer Symposium

(4-traders) Dec 10, 2014 - A cancer cell biologist from Harvard Medical School in Boston and a breast cancer endocrinologist from the Royal Marsden Hospital and Institute of Cancer Research in London are being honored today at the 37th annual San Antonio Breast Cancer Symposium as this year’s recipients of the prestigious Susan G. Komen® Brinker Awards for Scientific Distinction.
read article 

Luspatercept Data on Myelodysplastic Syndromes Selected for “Best of ASH” by the American Society of Hematology

( Dec 10, 2014 - Acceleron Pharma Inc. today announced that the presentation of data from the luspatercept phase 2 clinical trial in patients with lower risk myelodysplastic syndromes (MDS) was selected for Best of ASH at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition.
read article 

ASH: Pfizer Eyes Re-launch of Mylotarg

(PMLiVE [UK]) Dec 10, 2014 - Pfizer is hopeful that its Mylotarg product - pulled from the market in 2010 - could be resurrected on the strength of new data in acute myeloid leukaemia (AML).
read article 

To Address Breast Cancer Globally, Three Things Are Essential

(Forbes) Dec 10, 2014 - At one of the opening sessions of the 37th annual San Antonio Breast Cancer Symposium, Dr. Benjamin Anderson of the University of Washington spoke on breast cancer as a worldwide health problem. He, a surgeon and breast cancer specialist, leads the Breast Health Global Initiative (BHGI).
read article 

Merck Advancing Breast Cancer Drug to Mid-Stage

(ABC News/Associated Press) Dec 10, 2014 - Drugmaker Merck & Co. says it will advance a new cancer drug into bigger patient tests, after promising findings in an early study against a very aggressive, common type of breast cancer.
read article 

Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors

(Yahoo! Finance) Dec 10, 2014 - Study in APR positive endometrioid cancer patients.
read article